Skip to content
buyWeak

Paul Schimmel bought $50k of ATYR

director at aTYR PHARMA INC. 100,000 shares at an average of $0.50, traded May 27, 2026, filed May 28, 2026.

Conviction score
33
Value
$50k
100,000 shares
Holdings after
779,143
+15% from before
From 52-week low
+21%
low $0.40, close $0.48
From 52-week high
-93%
high $6.61, as of May 27, 2026

Score components

  • Role
    Director
    +15
  • Trade size
    $50k at market
    +7
  • Relative to holdings
    Holdings up 15%
    +3
  • Price context
    93% below the 52-week high
    +8
  • Cluster
    No other insider buying within 14 days
    0
  • Repeat buying
    First buy in 90 days
    0
  • Track record
    Too few past buys to judge (0 with prices)
    0

What happened after comparable buys

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

ATYROct 9, 2026 · close 0.25
Since filing May 28, 2026: -49.5%SPY +3.6% · excess -53.1%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001236447-26-000006, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
May 27, 2026POpen-market purchase
Common Stockindirect: See Footnote
+100,000$0.50$50k779,143May 28, 2026

Related signals

Other insiders at aTYR PHARMA INC and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
22Weak
ATYRsell 3
aTYR PHARMA INC
Jill Marie Broadfoot
Chief Financial Officer
$1,521
1,558 shares
-4%
15Weak
ATYRsell 3
aTYR PHARMA INC
Nancy Denyes
General Counsel
$1,091
1,118 shares
-3%
25Weak
ATYRsell 3
aTYR PHARMA INC
Sanjay Shukla
President and CEO
$3,655
3,745 shares
-2%
57Moderate
ATYRbuy
aTYR PHARMA INC
Paul Schimmel
director
$912k
1,000,000 shares
+242%
25Weak
ATYRbuy
aTYR PHARMA INC
Jane A Gross
director
$15k
3,750 shares
+63%
15Weak
ATYRsell 2
aTYR PHARMA INC
Jill Marie Broadfoot
Chief Financial Officer
$4,740
1,254 shares
-4%
8Weak
ATYRsell 2
aTYR PHARMA INC
Nancy Denyes
General Counsel
$3,398
899 shares
-3%
7Weak
ATYRsell
aTYR PHARMA INC
Jill Marie Broadfoot
Chief Financial Officer
$2,687
1,590 shares
-7%
51Moderate
ATYRbuy
aTYR PHARMA INC
Sanjay Shukla
President and CEO
$18k
15,000 shares
+16%
46Moderate
ATYRbuy
aTYR PHARMA INC
Sanjay Shukla
President and CEO
$17k
15,000 shares
+20%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Paul Schimmel bought $50k of ATYR | InsiderTell